巨细胞动脉炎的治疗:Meta分析及使用脆弱指数评估估计可靠性
该系统综述与随机效应Meta分析纳入10项随机对照试验(9项II期、1项III期,共645例),评估糖皮质激素节约策略对巨细胞动脉炎无复发生存的维持效果;托珠单抗、静脉糖皮质激素和甲氨蝶呤显著提高无复发可能性,相对危险度分别为3.54(2.28, 5.51)、5.11(1.39, 18.81)和1.54(1.02, 2.30);中位脆弱指数为4.5(范围1-28)。
要点
- 托珠单抗、静脉糖皮质激素和甲氨蝶呤显著提高巨细胞动脉炎无复发可能性。
- 中位脆弱指数为4.5(范围1-28),阴性试验中位脆弱指数4.5高于阳性试验的3.5。
- 各治疗脆弱指数范围:甲氨蝶呤1-8、抗TNF药物2-6、阿巴西普4、静脉糖皮质激素脉冲3、托珠单抗4-28。
核心结论
- 托珠单抗、静脉糖皮质激素和甲氨蝶呤提高巨细胞动脉炎受试者无复发的可能性。
- 巨细胞动脉炎糖皮质激素节约策略的评估长期依赖于不精确的试验,少数受试者结局反转即可改变显著性。
- 脆弱指数可用于风湿病学以简化统计显著性的沟通并克服P值的局限性。
研究设计与样本
- 系统综述与随机效应Meta分析,纳入10项随机对照试验(9项II期和1项III期,共645例受试者)。
- 纳入试验为巨细胞动脉炎中糖皮质激素节约策略用于无复发维持的随机对照试验。
- 使用脆弱指数简化结果展示,脆弱指数定义为使统计学显著结果变为不显著(或反之)所需改变结局状态的最少受试者数。
主要发现
- 托珠单抗显著改善无复发可能性,相对危险度为3.54(95%CI 2.28, 5.51)。
- 静脉糖皮质激素显著改善无复发可能性,相对危险度为5.11(95%CI 1.39, 18.81)。
- 甲氨蝶呤显著改善无复发可能性,相对危险度为1.54(95%CI 1.02, 2.30)。
- 中位脆弱指数为4.5(范围1-28),阴性随机对照试验(n=6)中位脆弱指数4.5高于阳性随机对照试验(n=4)的3.5。
- 各治疗脆弱指数范围:甲氨蝶呤1-8,抗TNF药物2-6,阿巴西普4,静脉糖皮质激素脉冲3,托珠单抗4-28。
关键数值与推荐
- 托珠单抗无复发相对危险度3.54(95%CI 2.28, 5.51)。
- 静脉糖皮质激素无复发相对危险度5.11(95%CI 1.39, 18.81)。
- 甲氨蝶呤无复发相对危险度1.54(95%CI 1.02, 2.30)。
- 中位脆弱指数4.5(范围1-28),阴性随机对照试验中位4.5,阳性随机对照试验中位3.5。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出巨细胞动脉炎糖皮质激素节约策略的评估长期依赖于不精确的试验。
- 原文指出少数受试者结局反转即可改变试验的统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To better communicate the results of randomized controlled trials (RCTs) of giant cell arteritis (GCA), we propose the use of the fragility index (FI), which is an intuitive measure defined as the minimum number of subjects whose status would have to change (e.g., from having the outcome to not) to render a statistically significant result nonsignificant, or vice-versa. METHODS: We conducted a systematic review and random-effects meta-analysis of RCTs of glucocorticoid (GC) sparing strategies for relapse-free maintenance in GCA, and used the FI to simplify the presentation of results. RESULTS: Ten RCTs (nine phase II and one phase III enrolling 645 subjects) were included. Tocilizumab, IV GC and methotrexate significantly improved the likelihood of being relapse free with relative risks and 95% confidence intervals of 3.54 (2.28, 5.51), 5.11 (1.39, 18.81) and 1.54 (1.02, 2.30); respectively. The median FI was 4.5 (range, 1-28), and was generally higher for negative RCTs (n = 6; median FI 4.5) than for positive RCTs (n = 4; median FI 3.5). The range of FI per treatment was (1-8) for methotrexate, (2-6) for anti-TNF agents, 4 for abatacept, 3 for IV GC pulses and (4-28) for tocilizumab. CONCLUSION: Tocilizumab, IV GC and methotrexate improve the likelihood of being relapse-free in subjects with GCA. Assessment of GC sparing strategies in GCA has long depended on imprecise trials that would change significance if outcomes were reversed for a handful of subjects. FI may be used in rheumatology to simplify communication of statistical significance and overcome limitations of p-value.
引用
- Berti A, Cornec D, Medina Inojosa JR, et al. Treatments for giant cell arteritis: Meta-analysis and assessment of estimates reliability using the fragility index. Semin Arthritis Rheum. 2018. PMID: 29496228. doi:10.1016/j.semarthrit.2017.12.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。